Legend Biotech (NasdaqGS:LEGN) is back in focus after the U.S. Food and Drug Administration cleared its IND for LB2501, an in vivo CAR-T candidate targeting CD19 and CD20 in relapsed or refractory B-cell malignancies.
Legend Biotech’s shares have reacted quickly to the FDA update, with a 1-day share price return of 3.99% and a 30-day share price return of 12.05%. However, this momentum comes off a weaker base, given the 1-year total shareholder return declined 38.81% and the 3-year total shareholder return fell 70.22%.
Capitalize on the renewed attention around Legend Biotech and compare it with a curated 20 high quality undiscovered gems that are also working on high-potential therapies yet still flying under most investors' radar.Bulls point to LB2501, rising revenue and a sharp discount to analyst value. Bears flag heavy losses and a long slide in Legend Biotech’s share price. Which side does the current valuation support?
Most Popular Narrative: 58% Undervalued
At a last close of $19.80 against a most-followed fair value estimate of $46.81, the prevailing view paints Legend Biotech as heavily discounted, with that gap hinging on how its cell therapy platform evolves over time.
Robust innovation pipeline, including next-generation CAR-Ts and in vivo/off-the-shelf cell therapy technologies (e.g., TaVec platform), positions Legend to capitalize on rising demand for advanced, personalized therapies amid secular increases in cancer incidence and sustained healthcare investment, supporting future revenue streams and risk diversification.
See why 26 investors see Legend Biotech as 58% undervalued.
Under this widely followed narrative, that $46.81 blended fair value uses a 7.62% discount rate and assumes Legend Biotech grows into a broader cell therapy franchise rather than remaining tied to a single product. The thesis leans on revenue growth forecasts, margin expansion from scale, and a pipeline that could add new indications beyond multiple myeloma.
Analysts in this framework also expect Legend Biotech to shift from a loss of $91.5 million today to positive earnings by 2029, with profit margins moving from negative territory toward 18.6%. To support the fair value, the stock would need to trade on a P/E multiple of 32.7x those projected earnings, which is higher than the current 17.1x level cited for the broader US biotech industry.
The spread between the current $19.80 price and the $46.81 narrative fair value is wide. Your own view on revenue growth, profitability and pipeline execution therefore needs to be equally strong before leaning on it. Sense check the 19.0% annual revenue growth assumption and margin path against your expectations for CARVYKTI uptake, competition and new products before adopting this valuation as your anchor.
Result: Fair Value of $46.81 (UNDERVALUED)
Still, the bullish Legend Biotech story can crack if CARVYKTI uptake disappoints or if heavy R&D spending keeps earnings in the red for longer than analysts model.
Find out about the key risks to this Legend Biotech narrative.
Next Steps
If the Legend Biotech story so far sounds divided, use that tension as a prompt to move quickly and review the numbers yourself. To see which potential upsides others are focusing on, review the 4 key rewards.
Looking for more Legend Biotech style investment ideas?
Legend Biotech might be your starting point, but you give yourself far more options when you scan a wider field of opportunities using a focused stock screener.
- Target potential mispricings by scanning a curated list of companies trading at attractive valuations through the 33 high quality undervalued stocks.
- Prioritize resilience by filtering for companies with strong finances using the list of solid balance sheet and fundamentals (25 results).
- Seek powerful upside potential by hunting for early-stage opportunities that still fly under the radar through the 20 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com